- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02063659
Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)
January 26, 2018 updated by: Lexicon Pharmaceuticals
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
76
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Kogara, New South Wales, Australia, 2217
- Lexicon Investigational Site
-
St. Leonards, New South Wales, Australia, 2065
- Lexicon Investigational Site
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Lexicon Investigational Site
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Lexicon Investigational Site
-
-
-
-
-
Edegem, Belgium, B-2650
- Lexicon Investigational Site
-
Gent, Belgium, 9000
- Lexicon Investigational Site
-
Yvoir, Belgium, 5530
- Lexicon Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N4N2
- Lexicon Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B0J1N0
- Lexicon Investigational Site
-
-
-
-
-
Clichy, France, 92118
- Lexicon Investigational Site
-
Lille, France, 59037
- Lexicon Investigational Site
-
Lyon, France, 69347
- Lexicon Investigational Site
-
Marseille, France, 13385
- Lexicon Investigational Site
-
Strasbourg, France, 67098
- Lexicon Investigational Site
-
Villejuif, France, 94805
- Lexicon Investigational Site
-
-
-
-
-
Bad Berka, Germany, 99437
- Lexicon Investigational Site
-
Berlin, Germany, 13353
- Lexicon Investigational Site
-
Hamburg, Germany, 20246
- Lexicon Investigational Site
-
Heidelberg, Germany, 69120
- Lexicon Investigational Site
-
Lubeck, Germany, 23538
- Lexicon Investigational Site
-
Mainz, Germany, 55131
- Lexicon Investigational Site
-
Marburg, Germany, 35043
- Lexicon Investigational Site
-
Munich, Germany, 81377
- Lexicon Investigational Site
-
Neuss, Germany, 41464
- Lexicon Investigational Site
-
-
-
-
-
Jerusalem, Israel, 91120
- Lexicon Investigational Site
-
-
-
-
-
Noord Brahant, Netherlands, 5631BM
- Lexicon Investigational Site
-
Rotterdam, Netherlands, 3015 CE
- Lexicon Investigative Site
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1066X
- Lexicon Investigational Site
-
Amsterdam, Noord-Holland, Netherlands, 1105 AZ
- Lexicon Investigational Site
-
-
-
-
-
Barcelona, Spain, 08035
- Lexicon Investigational Site
-
Barcelona, Spain, 08907
- Lexicon Investigational Site
-
Madrid, Spain, 28034
- Lexicon Investigational Site
-
Madrid, Spain, 28040
- Lexicon Investigational Site
-
Sevilla, Spain, 41013
- Lexicon Investigational Site
-
-
-
-
-
Uppsala, Sweden, 75185
- Lexicon Investigational Site
-
-
-
-
-
Basingstoke Hampshire, United Kingdom, RG249NA
- Lexicon Investigational Site
-
Coventry, United Kingdom, CV22DX
- Lexicon Investigational Site
-
London, United Kingdom, SE59RS
- Lexicon Investigational Site
-
London, United Kingdom, NW3 2QG
- Lexicon Investigational Site
-
London, United Kingdom, W12 OHS
- Lexicon Investigational Site
-
Manchester, United Kingdom, M204BX
- Lexicon Investigational Site
-
Newcastle upon Tyne, United Kingdom, NE1 4LP
- Lexicon Investigational Site
-
-
-
-
California
-
Stanford, California, United States, 94305
- Lexicon Investigational Site
-
-
Florida
-
Orlando, Florida, United States, 32806
- Lexicon Investigational Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Lexicon Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Lexicon Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Lexicon Investigational Site
-
-
New York
-
Buffalo, New York, United States, 14263
- Lexicon Investigational Site
-
New York, New York, United States, 10029
- Lexicon Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Lexicon Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients ≥ 18 years of age
- All patients of reproductive potential must agree to use an adequate method of contraception during the study and for 12 weeks after the Follow-up visit.
- Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor
- Documented history of carcinoid syndrome
- Patient is able and willing to provide written informed consent prior to participation
Exclusion Criteria:
- Presence of diarrhea attributed to any condition other than carcinoid syndrome.
- Presence of 12 or more watery bowel movements per day
- Positive stool examination for enteric pathogens, pathogenic ova or parasites, of Clostridium difficile at Screening
- Karnofsky Performance Status ≤ 60%
- Presence of any clinically significant laboratory, medical history, or physical examination findings deemed unacceptable by the Investigator
- A history of short bowel syndrome
- History of constipation within 2 years of Screening
- Life expectancy < 12 months from Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 250 mg Telotristat Etiprate
Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
|
Telotristat etiprate tablets
Other Names:
Placebo-matching telotristat etiprate tablets
|
Experimental: 500 mg Telotristat Etiprate
Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
|
Telotristat etiprate tablets
Other Names:
Placebo-matching telotristat etiprate tablets
|
Placebo Comparator: Placebo
Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
|
Placebo-matching telotristat etiprate tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period
Time Frame: First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.1 Weeks)
|
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
A TEAE was an AE reported after the first dose of randomized treatment on Day 1.
|
First dose of study drug to within 30 days of last dose of study drug in the Double-Blind Treatment Period (Up to 17.1 Weeks)
|
Primary: Percent Change From Baseline in Urinary 5-hydroxyindoleacetic Acid (u5-HIAA) Levels
Time Frame: Baseline and 12 Weeks
|
u5-HIAA is a standard test used in clinical practice to assess neuroendocrine tumor (NET) activity and is collected as a 24-hour urine specimen.
A negative change from Baseline indicates improvement.
|
Baseline and 12 Weeks
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Extension Period
Time Frame: First dose of study drug to within 30 days of last dose of study drug in the Open-Label Extension Period (Up to 52.6 Weeks)
|
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
A TEAE was an AE reported after the first dose of randomized treatment on Day 1.
|
First dose of study drug to within 30 days of last dose of study drug in the Open-Label Extension Period (Up to 52.6 Weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Number of Bowel Movements (BMs) Per Day Averaged Over 12 Weeks
Time Frame: Baseline and 12 weeks
|
Participants recorded the number of bowel movements per day in a daily diary.
The total number of BMs per day were averaged over the 12-week period.
A negative change from Baseline indicates improvement.
|
Baseline and 12 weeks
|
Change From Baseline in Stool Form/Consistency Averaged Across All Time-Points
Time Frame: Baseline and 12 Weeks
|
Participants assessed stool form/consistency of a BM using the Bristol Stool Form Scale where: 1=hard lumps to 7=watery liquid.
The daily scores were averaged over the 12-week period.
A negative change indicates improvement.
|
Baseline and 12 Weeks
|
Change From Baseline in the Number of Daily Cutaneous Flushing Episodes Averaged Across All Time-Points
Time Frame: Baseline and 12 Weeks
|
Participants recorded the number daily flushing episodes per day in a daily diary.
The total number of flushing episodes per day were averaged over the 12-week period.
A negative change from Baseline indicates improvement.
|
Baseline and 12 Weeks
|
Change From Baseline in Abdominal Pain Averaged Across All Time-Points
Time Frame: Baseline and 12 Weeks
|
Participants recorded abdominal pain in a daily diary.
Participants evaluated the level of any abdominal pain using an 11-point numeric rating scale, where: 0=no pain to 10=worst pain ever experienced.
The average daily abdominal pain was averaged over the 12-week period.
A negative change from Baseline indicates improvement.
|
Baseline and 12 Weeks
|
Change in the Frequency of Rescue Short-acting, Somatostatin Analog (SSA) Used to Treat Carcinoid Syndrome Symptoms Averaged Across All Time-Points
Time Frame: Baseline and 12 weeks
|
The frequency (the number of times) the participant used rescue with SSA to control symptoms was recorded in a daily diary.
The daily number of rescue treatments with SSA was averaged over the 12- week period.
A negative change from Baseline (less use of SSA) indicates improvement.
|
Baseline and 12 weeks
|
Change From Baseline in the Number of Daily BMs Averaged Over the 12-Week Double-Blind Period, Among Participants Who Were Not Receiving SSA Therapy at Baseline
Time Frame: Baseline and 12 Weeks
|
Participants recorded the number of bowel movements per day in a daily diary.
The total number of BMs per day were averaged over the 12-week period.
A negative change from Baseline indicates improvement.
|
Baseline and 12 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pablo LaPuerta, MD, Lexicon Pharmaceuticals, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Clin Ther. 2021 Oct;43(10):1779-1785. doi: 10.1016/j.clinthera.2021.08.014. Epub 2021 Sep 28.
- Dillon JS, Kulke MH, Horsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2021 Mar;52(1):212-221. doi: 10.1007/s12029-020-00375-2.
- Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Horsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2014
Primary Completion (Actual)
March 29, 2016
Study Completion (Actual)
March 29, 2016
Study Registration Dates
First Submitted
February 12, 2014
First Submitted That Met QC Criteria
February 12, 2014
First Posted (Estimate)
February 14, 2014
Study Record Updates
Last Update Posted (Actual)
February 26, 2018
Last Update Submitted That Met QC Criteria
January 26, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Disease
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Drug-Related Side Effects and Adverse Reactions
- Syndrome
- Carcinoid Tumor
- Malignant Carcinoid Syndrome
- Serotonin Syndrome
Other Study ID Numbers
- LX1606.1-303-CS
- LX1606.303 (Other Identifier: Lexicon Pharmaceuticals, Inc.)
- 2013-001543-31 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoid Syndrome
-
Crinetics Pharmaceuticals Inc.Active, not recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of PancreasUnited States, Brazil, Argentina, Canada, Mexico, Peru, Poland
-
IpsenTerminatedCarcinoid SyndromeSpain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
-
IpsenTerminatedMalignant Carcinoid SyndromeUnited States
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeGermany, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompleted
-
IpsenCompletedCarcinoid SyndromeUnited States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeUnited States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
-
Endo PharmaceuticalsTerminatedCarcinoid SyndromeUnited States
-
IpsenCompleted
-
IpsenCompletedNeuroendocrine Tumors | Carcinoid SyndromeFrance, Italy, United Kingdom, Poland, Spain, Hungary, Czechia, Israel
Clinical Trials on Telotristat etiprate
-
Lexicon PharmaceuticalsCompleted
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeUnited States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
-
Lexicon PharmaceuticalsCompletedHepatic ImpairmentUnited States
-
IpsenCompletedHepatic ImpairmentMoldova, Republic of, Romania
-
IpsenCompletedRenal ImpairmentMoldova, Republic of, Belgium, Germany, Romania
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeGermany, United Kingdom
-
Lexicon PharmaceuticalsCompletedCarcinoid SyndromeUnited States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
-
Lexicon PharmaceuticalsCompletedUlcerative ColitisUnited States, Lithuania, Poland, Slovakia
-
Lexicon PharmaceuticalsCompletedDrug InteractionsUnited States
-
Lexicon PharmaceuticalsCompleted